Stock listing
Stuttgart:EN9 Enzymatica AB Aktie
German listing (Stuttgart) of Enzymatica AB · home listing Stockholm:ENZY
Follow Enzymatica AB into a list and get an email when it puts out news.
Home listing price · OMXSTO:ENZY
2.32 SEK -0.08 (-3.3%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, OMXSTO:ENZY
- Day range
- 2.20 – 2.49 SEKNov 20, 2026
- Volume
- 50,892 sharesNov 20, 2026
- Market cap
- 563.1M SEKAt the close on Nov 20, 2026 · price × 242.7M shares outstanding
- 52-week range
- 1.55 – 3.40 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 219,881 SEKMedian day 73,156 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Stockholm:ENZY · Home | 2.32 SEK | -0.08 (-3.3%) | 50,892 | 2.29 | 2.49 | 2.20 | 2.40 | Close on Nov 20, 2026 |
| Frankfurt:EN9 | €0.177 EUR | -0.009 (-4.6%) | — | €0.173 | €0.177 | €0.173 | €0.185 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:ENZY · SEK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 2.32 | -0.08 | -3.3% | 2.29 | 2.49 | 2.20 | 50,892 | |
| 2.40 | +0.03 | +1.3% | 2.37 | 2.40 | 2.32 | 28,706 | |
| 2.37 | -0.08 | -3.3% | 2.45 | 2.45 | 2.33 | 34,088 | |
| 2.45 | -0.06 | -2.4% | 2.44 | 2.54 | 2.40 | 32,170 | |
| 2.51 | +0.05 | +2.0% | 2.41 | 2.60 | 2.41 | 56,249 | |
| 2.46 | -0.03 | -1.2% | 2.49 | 2.54 | 2.38 | 181,650 | |
| 2.49 | +0.04 | +1.6% | 2.43 | 2.55 | 2.39 | 113,960 | |
| 2.45 | +0.20 | +8.9% | 2.27 | 2.45 | 2.27 | 79,009 | |
| 2.25 | -0.34 | -13.1% | 2.59 | 2.64 | 2.25 | 296,804 | |
| 2.59 | +0.39 | +17.7% | 2.20 | 2.59 | 2.19 | 546,727 | |
| 2.20 | -0.10 | -4.3% | 2.30 | 2.30 | 2.20 | 49,613 | |
| 2.30 | +0.03 | +1.3% | 2.29 | 2.45 | 2.20 | 175,379 | |
| 2.27 | +0.14 | +6.6% | 2.19 | 2.27 | 2.19 | 87,812 | |
| 2.13 | -0.02 | -0.9% | 2.16 | 2.25 | 1.985 | 396,649 | |
| 2.15 | +0.11 | +5.4% | 2.00 | 2.15 | 1.95 | 359,887 | |
| 2.04 | +0.11 | +5.7% | 1.975 | 2.08 | 1.89 | 99,958 | |
| 1.93 | -0.05 | -2.5% | 1.975 | 1.975 | 1.855 | 128,392 | |
| 1.98 | +0.035 | +1.8% | 1.945 | 1.98 | 1.905 | 42,693 | |
| 1.945 | -0.005 | -0.3% | 1.95 | 1.95 | 1.825 | 48,364 | |
| 1.95 | +0.005 | +0.3% | 1.95 | 2.10 | 1.885 | 124,325 | |
| 1.945 | +0.035 | +1.8% | 1.90 | 1.945 | 1.90 | 47,296 | |
| 1.91 | +0.01 | +0.5% | 1.90 | 1.985 | 1.855 | 57,063 | |
| 1.90 | +0.20 | +11.8% | 1.70 | 2.00 | 1.70 | 191,284 | |
| 1.70 | -0.06 | -3.4% | 1.75 | 1.77 | 1.695 | 46,271 | |
| 1.76 | +0.06 | +3.5% | 1.695 | 1.76 | 1.67 | 99,076 | |
| 1.70 | -0.07 | -4.0% | 1.76 | 1.77 | 1.70 | 440,245 | |
| 1.77 | +0.065 | +3.8% | 1.775 | 1.775 | 1.695 | 246,346 | |
| 1.705 | -0.04 | -2.3% | 1.75 | 1.75 | 1.665 | 52,598 | |
| 1.745 | +0.045 | +2.6% | 1.705 | 1.745 | 1.70 | 13,368 | |
| 1.70 | -0.03 | -1.7% | 1.735 | 1.745 | 1.70 | 20,989 | |
| 1.73 | -0.05 | -2.8% | 1.78 | 1.79 | 1.695 | 75,633 | |
| 1.78 | -0.01 | -0.6% | 1.785 | 1.785 | 1.71 | 31,245 | |
| 1.79 | +0.055 | +3.2% | 1.675 | 1.79 | 1.675 | 24,436 | |
| 1.735 | +0.025 | +1.5% | 1.65 | 1.76 | 1.645 | 98,369 | |
| 1.71 | -0.015 | -0.9% | 1.635 | 1.715 | 1.635 | 32,140 | |
| 1.725 | -0.005 | -0.3% | 1.68 | 1.725 | 1.605 | 83,464 | |
| 1.73 | +0.065 | +3.9% | 1.635 | 1.73 | 1.63 | 49,134 | |
| 1.665 | -0.025 | -1.5% | 1.685 | 1.72 | 1.625 | 15,513 | |
| 1.69 | -0.01 | -0.6% | 1.565 | 1.725 | 1.565 | 113,911 | |
| 1.70 | 0.00 | 0.0% | 1.67 | 1.87 | 1.55 | 139,694 | |
| 1.70 | +0.005 | +0.3% | 1.70 | 1.735 | 1.675 | 97,685 | |
| 1.695 | -0.10 | -5.6% | 1.775 | 1.78 | 1.67 | 241,202 | |
| 1.795 | -0.065 | -3.5% | 1.86 | 1.86 | 1.77 | 144,266 | |
| 1.86 | +0.01 | +0.5% | 1.845 | 1.97 | 1.82 | 36,815 | |
| 1.85 | -0.05 | -2.6% | 1.91 | 1.91 | 1.85 | 70,678 | |
| 1.90 | -0.07 | -3.6% | 1.91 | 1.97 | 1.90 | 40,574 | |
| 1.97 | -0.07 | -3.4% | 1.935 | 1.995 | 1.925 | 36,648 | |
| 2.04 | -0.03 | -1.4% | 2.02 | 2.09 | 1.95 | 47,335 | |
| 2.07 | -0.08 | -3.7% | 2.14 | 2.14 | 2.06 | 12,714 | |
| 2.15 | 0.00 | 0.0% | 2.16 | 2.19 | 2.08 | 47,561 | |
| 2.15 | +0.05 | +2.4% | 2.09 | 2.15 | 2.01 | 157,192 | |
| 2.10 | +0.08 | +4.0% | 2.01 | 2.16 | 1.955 | 149,511 | |
| 2.02 | 0.00 | 0.0% | 2.13 | 2.16 | 1.92 | 118,324 | |
| 2.02 | +0.17 | +9.2% | 1.855 | 2.22 | 1.855 | 237,957 | |
| 1.85 | +0.015 | +0.8% | 1.85 | 1.85 | 1.80 | 116,529 | |
| 1.835 | -0.01 | -0.5% | 1.815 | 1.855 | 1.805 | 43,567 | |
| 1.845 | +0.035 | +1.9% | 1.79 | 1.865 | 1.785 | 69,470 | |
| 1.81 | +0.01 | +0.6% | 1.80 | 1.82 | 1.765 | 102,699 | |
| 1.80 | +0.04 | +2.3% | 1.75 | 1.80 | 1.745 | 52,304 | |
| 1.76 | -0.14 | -7.4% | 1.89 | 1.89 | 1.65 | 177,342 | |
| 1.90 | +0.05 | +2.7% | 1.925 | 1.925 | 1.90 | 1,530 | |
| 1.85 | -0.01 | -0.5% | 1.855 | 1.905 | 1.85 | 61,865 | |
| 1.86 | -0.065 | -3.4% | 1.90 | 1.94 | 1.85 | 79,098 | |
| 1.925 | -0.02 | -1.0% | 1.895 | 1.945 | 1.89 | 11,807 |
Splits
1 split · OMXSTO:ENZY · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 75-for-73 | Split |
- Ticker
- Stuttgart:EN9
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Stuttgart
- Currency
- EUR
What changed lately
Latest news release · Jun 9, 2026
Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics
Latest news
Enzymatica appoints Marketing and Sales Director to accelerate ColdZyme’s continued growth in the Nordics
Jun 9, 2026
Closed 2.75 (-1.1%) on Jun 9, 2026
Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement
Apr 28, 2026
Closed 2.64 (-1.1%) on Apr 28, 2026
Enzymatica publishes annual report for 2025
Apr 14, 2026
Closed 2.95 (0.0%) on Apr 14, 2026
Enzymatica and STADA sign partnership agreement for Germany and Austria
Mar 31, 2026
Closed 3.18 (+4.6%) on Mar 31, 2026
Year-end report 2025: New CEO takes the helm - initiates the next phase of Enzymatica's international expansion
Feb 18, 2026
Closed 1.85 (+12.5%) on Feb 18, 2026
Enzymatica appoints Acting CFO during transition period
Dec 11, 2025
Closed 1.90 (+0.5%) on Dec 11, 2025
Enzymatica enters partnership with the UK Sports Institute to strengthen elite athlete health
Nov 26, 2025
Closed 1.95 (+5.4%) on Nov 26, 2025
Enzymatica AB on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 7 in the last 12 months · 13 in all · newest Jun 9, 2026 · oldest 2025
- Decks
- 1 deck · latest 2021
Where Enzymatica AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:ENZY · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A1WZEV | LS Exchange | Germany | EUR |
| Lang & Schwarz:A1WZEV | Lang & Schwarz | Germany | EUR |
| gettex:EN9 | gettex | Germany | EUR |
| Munich:EN9 | Munich | Germany | EUR |
| Frankfurt:EN9 | Frankfurt | Germany | EUR |
| Stuttgart:EN9 · This page | Stuttgart | Germany | EUR |
Valuation
EV/sales 11.1× against a median of 2.2×: the highest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 570.3M SEK
- P/E
- Loss
- EV/sales
- 11.1×
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 6.0×
- Gross margin
- 58.8%
- Operating margin
- −79.4%
- Net margin
- −80.5%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Enzymatica AB · OMXSTO:ENZY | US$55.08M | US$55.77M | n/a | 11.1× | n/a | 6.0× | −80.5% | 0.1× | n/a |
| REMED Co., Ltd. · KRX:302550 | US$57.50M | US$51.61M | 37.5× | 2.5× | 20.4× | 2.0× | 7.6% | 0.1× | n/a |
| Vincent Medical Holdings Limited · HKEX:1612 | US$57.26M | US$62.46M | 4.3× | 0.5× | 2.9× | 0.6× | 11.2% | 0.3× | n/a |
| OK Biotech Co., Ltd. · TWSE:4155 | US$55.10M | US$75.16M | 7.5× | 1.6× | 7.9× | 0.7× | 15.8% | 0.4× | n/a |
| LENSAR, Inc. · NASDAQ:LNSR | US$54.83M | US$44.40M | 1.6× | 0.7× | 18.0× | 5.0× | 56.1% | 0.2× | 0.76 |
| P&S Robotics Co., Ltd. · KRX:460940 | US$54.71M | US$33.83M | 26.6× | 5.9× | 36.6× | 1.7× | 36.0% | 0.0× | n/a |
| Creo Medical Group PLC · LSE:CREO | US$54.06M | US$49.48M | 7.8× | 6.3× | n/a | 0.9× | 88.3% | 0.1× | n/a |
| Crystalvue Medical Co Ltd · TPEX:6527 | US$53.82M | US$52.19M | 12.1× | 1.8× | 8.7× | 1.7× | 15.5% | 0.0× | n/a |
| 3D Global Biotech Inc. · TPEX:6808 | US$53.26M | US$38.17M | 26.4× | 6.1× | 17.5× | 2.4× | 32.2% | 0.0× | n/a |
| Outset Medical, Inc. · NASDAQ:OM | US$53.03M | US$14.77M | n/a | 0.1× | n/a | 0.6× | −58.3% | 1.2× | 1.74 |
| NeurAxis, Inc. · AMEX:NRXS | US$52.99M | US$48.80M | n/a | 7.5× | n/a | 14.6× | −185.2% | 0.1× | 1.77 |
| Median of the others | US$54.38M | US$49.14M | 9.9× | 2.2× | 17.5× | 1.7× | 15.6% | 0.1× | 1.74 |
Team and board
| Officer | Role |
|---|---|
| Sana Alajmovic | Chief Executive Officer of Enzymatica AB |
| Holger Lembrér | CFO |
| Anja Trägårdh | Corporate Communications |
| Katja Margell | Director of Investor Relations & Corporate Affairs |
| Joakim Tingström Nordin | Nordic Marketing and Sales Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 30, 2026 | +8.0% |
| Q2 2026 | Jul 17, 2026 | +0.5% |
| Q1 2026 | Apr 27, 2026 · Before open | −4.6% |
| Q4 2025 | Feb 16, 2026 · Before open | −1.2% |
| Q3 2025 | Oct 30, 2025 · Before open | +2.0% |
| Q2 2025 | Jul 27, 2025 · Before open | +0.4% |
| Q1 2025 | Apr 29, 2025 · Before open | −6.9% |
| Q4 2024 | Feb 18, 2025 · Before open | 0.0% |
| Q3 2024 | Nov 7, 2024 · Before open | +0.6% |
| Q2 2024 | Jul 18, 2024 · Before open | −16.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Apr 25, 2024 · Before open | −8.2% |
| Q4 2023 | Feb 16, 2024 · Before open | −6.2% |
| Q3 2023 | Nov 7, 2023 · Before open | −11.1% |
| Q2 2023 | Jul 18, 2023 · Before open | +5.8% |
| Q1 2023 | Apr 27, 2023 · Before open | +17.7% |
| Q4 2022 | Feb 17, 2023 · Before open | −18.8% |
| Q3 2022 | Nov 2, 2022 · Before open | −7.0% |
| Q2 2022 | Jul 19, 2022 · Before open | −1.4% |
| Q1 2022 | Apr 28, 2022 · Before open | −13.9% |
| Q4 2021 | Feb 17, 2022 · Before open | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2021) | Investor deck | 32 slides | 2021 |
Financials
Annual, in SEK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.9M | 45.6M | 50.9M | 48.9M | 57.2M | 111.2M | 61.3M | 52.6M | 59.4M | 36.5M |
| Cost of revenue | 20.8M | 14.9M | 19.0M | 20.5M | 23.9M | 35.3M | 16.4M | 15.8M | 23.1M | 14.3M |
| Gross profit | 33.1M | 30.7M | 31.9M | 28.5M | 33.4M | 76.0M | 44.9M | 36.8M | 36.3M | 22.2M |
| Research and development | 15.7M | 15.5M | 15.2M | 26.5M | 24.2M | 22.5M | 28.5M | 20.8M | 14.4M | 12.3M |
| Selling, general and administrative | 42.2M | 41.3M | 39.4M | 38.7M | 32.8M | 40.7M | 29.0M | 28.6M | 27.3M | 26.2M |
| Operating income | -52.2M | -52.1M | -48.1M | -68.2M | -45.2M | -12.1M | -41.7M | -40.6M | -30.2M | -46.2M |
| Depreciation and amortization | 5.40M | 5.81M | 6.51M | 7.78M | 6.63M | 7.03M | 7.08M | 6.23M | 5.36M | 2.79M |
| EBITDA | -46.8M | -46.2M | -41.6M | -60.4M | -38.6M | -5.03M | -34.6M | -34.3M | -24.9M | -43.4M |
| Interest expense | 1.23M | 1.91M | 2.09M | 997.0K | 889.0K | 804.0K | 1.47M | 2.34M | 536.0K | 1.43M |
| Income before tax | -51.8M | -53.3M | -49.7M | -68.7M | -45.7M | -13.1M | -41.9M | -42.1M | -30.9M | -46.8M |
| Income tax | -51.0K | -159.0K | 9.00K | -90.0K | -307.0K | 159.0K | -961.0K | 429.0K | 576.0K | -1.83M |
| Net income | -51.9M | -53.2M | -49.7M | -68.7M | -45.4M | -13.2M | -41.0M | -42.6M | -31.4M | -45.0M |
| Earnings per share, basic | -0.21 | -0.28 | -0.28 | -0.41 | -0.31 | -0.09 | -0.29 | -0.45 | -0.35 | -0.68 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 33.1M | 75.2M | 8.37M | 50.7M | 31.6M | 24.0M | 29.3M | 70.3M | 10.9M | 35.6M |
| Receivables | 10.6M | 13.6M | 12.5M | 17.7M | 18.8M | 32.8M | 16.0M | 11.0M | 17.8M | 10.3M |
| Inventory | 18.9M | 16.7M | 11.5M | 11.5M | 12.4M | 10.5M | 7.00M | 5.55M | 2.69M | 6.99M |
| Current assets | 65.0M | 112.0M | 38.8M | 84.8M | 64.8M | 71.5M | 54.7M | 90.0M | 32.4M | 56.3M |
| Property, plant and equipment | 10.4M | 14.4M | 16.5M | 16.4M | 15.2M | 10.3M | 6.78M | 4.54M | 4.87M | 4.38M |
| Goodwill | 63.2M | 63.2M | 63.2M | 63.2M | 63.2M | 63.2M | 63.2M | 63.2M | 63.2M | 63.2M |
| Total assets | 142.0M | 195.2M | 125.9M | 174.4M | 157.0M | 162.0M | 147.7M | 185.2M | 133.8M | 162.6M |
| Accounts payable | 8.75M | 9.81M | 7.37M | 6.67M | 7.61M | 13.9M | 10.4M | 10.2M | 6.31M | 4.48M |
| Current liabilities | 17.8M | 17.8M | 32.4M | 27.0M | 30.9M | 53.3M | 24.6M | 21.6M | 17.5M | 13.2M |
| Long-term debt | 8.00K | 0 | 14.9M | 20.9M | 0 | 233.0K | 2.09M | 3.87M | 5.65M | 5.83M |
| Total debt | 1.02M | 2.20M | 18.1M | 22.3M | 2.60M | 14.5M | 5.57M | 4.78M | 8.31M | 8.57M |
| Total liabilities | 17.8M | 18.9M | 49.3M | 48.1M | 32.1M | 55.4M | 28.5M | 25.5M | 23.1M | 20.6M |
| Shareholders' equity | 124.2M | 176.4M | 76.6M | 126.3M | 125.0M | 106.6M | 119.2M | 159.7M | 110.3M | 141.7M |
| Shares outstanding | 242.7M | 192.7M | 177.6M | 166.9M | 146.7M | 142.9M | 142.9M | 95.3M | 90.9M | 66.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -41.0M | -60.5M | -40.3M | -64.6M | -35.9M | -10.7M | -37.6M | -28.8M | -22.5M | -38.4M |
| Capital spending | -231.0K | -393.0K | -730.0K | -3.72M | -6.13M | -4.84M | -866.0K | -520.0K | -1.26M | -13.9M |
| Free cash flow | -41.2M | -60.9M | -41.0M | -68.3M | -42.0M | -15.5M | -38.4M | -29.3M | -23.8M | -52.3M |
| Cash from investing | -231.0K | -393.0K | -730.0K | -3.72M | -6.13M | -4.84M | -866.0K | -520.0K | -1.26M | -19.0M |
| Cash from financing | -789.0K | 127.7M | -1.39M | 87.4M | 49.5M | 10.0M | -2.53M | 88.7M | -846.0K | 84.6M |
| Share buybacks | 390.0K | 159.3M | 0 | 74.7M | 66.7M | 2.54M | 0 | 98.7M | 0 | 100.2M |
| Change in cash | -42.1M | 66.8M | -42.3M | 19.1M | 7.60M | -5.30M | -41.0M | 59.4M | -24.7M | 27.5M |
Cap table
Built by 6ix from Enzymatica AB’s releases
- Common shares
- 242,735,108
- Fully diluted
- 242,735,108
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 242,735,108 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 242,735,108 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Anja Trägårdh | Corporate Communications · Since at least Mar 31, 2026 |
| Holger Lembrér | CFO · Since at least Feb 18, 2026 |
| Joakim Tingström Nordin | Nordic Marketing and Sales Director · Since at least Jun 9, 2026 |
| Sana Alajmovic | Chief Executive Officer of Enzymatica AB · Since at least Feb 18, 2026 |
Log in to ask 6ix AI your own questions about Enzymatica AB.